B
Bullisch
Bullisch · 25%RGC
$19.32
Szenariopreis
$8.110
-0.079 (-0.98%)Zum Schluss
Loading chart…
- Hoch
- 9.470
- Eröffnung
- 8.200
- Volumengewichteter Durchschnittskurs
- 8.47
- Volumen
- 658.00K
- Marktkap.
- 45.81M
- Tief
- 7.820
- Umsatz
- 5.57M
- EV/EBITDA, TTM
- 0.00
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
KI-Analyse of Regencell Bioscience Holdings Ltd (RGC)
HaltenRegencell Bioscience Holdings Ltd is currently priced at 7.35, with a recent RSI of 66.989 indicating it is approaching overbought territory. The stock has seen a 5-day change of +7.77%, but it remains down 64.22% year-to-date, suggesting significant long-term challenges. While there was a notable surge of 35% amid a short squeeze, the overall trend shows a decline of 59.14% over the past year, indicating that caution is warranted. The main risk is the negative P/E ratio of -633.62, reflecting ongoing financial difficulties.
Analystenbewertungen (15)
Kaufen
9 Kaufen
5 Halten
1 Verkaufen
Aktuell: 8.11
Tief
—
Durchschnitt
—
Hoch
—
Bewertungskennzahlen
Das aktuelle erwartete KGV von Regencell Bioscience Holdings Ltd (RGC) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von 0.00.
Alphio-AI-Kursszenarien für RGC
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Event-Zeitleiste
News
2.007-01seekingalphaRegencell Bioscience Shares Surge 35% Amid Short Squeeze
7.006-23PRnewswireRegencell Bioscience Faces Class Action Lawsuit
7.006-23GlobenewswireRegencell Bioscience Class Action Alert for Investors
- 7.006-23PRnewswire
Regencell Securities Class Action Reminder
- 7.006-22Globenewswire
Regencell Faces Class Action Lawsuit for Investor Rights
RGC FAQ – beantwortet von Alphio AI
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients. It operates in the Healthcare sector (MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS industry).
Regencell Bioscience Holdings Ltd is currently priced at 7.35, with a recent RSI of 66.989 indicating it is approaching overbought territory. The stock has seen a 5-day change of +7.77%, but it remains down 64.22% year-to-date, suggesting significant long-term challenges. While there was a notable surge of 35% amid a short squeeze, the overall trend shows a decline of 59.14% over the past year, indicating that caution is warranted. The main risk is the negative P/E ratio of -633.62, reflecting ongoing financial difficulties.
15 analysts cover RGC: 9 rate it Buy, 5 Hold and 1 Sell.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.